Abstract 240P
Background
Cervical cancer is one of the leading causes of morbidity and mortality among women from cancer of the reproductive organs in developing countries. The purpose of this study is to analyze the dynamics of morbidity and mortality from cervical cancer in the Republic of Kazakhstan.
Methods
Mortality and morbidity rates were calculated for the period 2007-2016. 95% confidence intervals are presented. Incidence of and mortality rates were calculated per 100,000 (0/0000) of female population. All statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) software, version 20.0 for Windows.
Results
For the period from 2007 to 2016, the incidence rates of cervical cancer were analyzed, which varied from 15.24 to 18.83 per 100,000 of female population. Mortality rates tended to decline over the 10-year period under review in 2007, reaching 7.8 to 7.0 per 100,000 of female population in 2016. There is a difference in morbidity and mortality from cervical cancer between different regions of Kazakhstan. An analysis of the distribution of the incidence in the Republic of Kazakhstan revealed the highest incidence rates in the northern region of the country 28.2 (95% CI: 23.6-33.5) and the north-eastern region 27.3 (95% CI: 22.4-32.9) per 100,000 of female population. On the other hand, the lowest morbidity and mortality rates were found in the southern region substituted 10.4 (95% CI: 7.4-14.2) and 5.4 (95% CI: 4.3-6.8) per 100,000 of female population respectively.
Conclusions
Thus, the incidence of cervical cancer in the Republic of Kazakhstan has increased over the 10-year period in question, while mortality rates have been gradually decreasing. Such trends can result from the national screening program which was implemented in Kazakhstan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract